dutasteride ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
testosterone reductase inhibitors 973 164656-23-9

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • dutasteride
  • veltride
  • avodart
  • avolve
  • GG745
  • GG-745
A 5-ALPHA-REDUCTASE INHIBITOR that is reported to inhibit both type-1 and type2 isoforms of the enzyme and is used to treat BENIGN PROSTATIC HYPERPLASIA.
  • Molecular weight: 528.54
  • Formula: C27H30F6N2O2
  • CLOGP: 4.94
  • LIPINSKI: 1
  • HAC: 4
  • HDO: 2
  • TPSA: 58.20
  • ALOGS: -5.77
  • ROTB: 4

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.50 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 0.50 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.01 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 60 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

DateAgencyCompanyOrphan
Nov. 20, 2001 FDA GLAXOSMITHKLINE

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Accidental exposure to product 39.95 38.02 10 153 27395 63461464

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug dispensed to wrong patient 168.02 12.26 45 26613 479 34929794
Conjunctivitis allergic 124.56 12.26 43 26615 1127 34929146
Mycotic allergy 116.82 12.26 35 26623 573 34929700
Spirometry abnormal 114.97 12.26 36 26622 688 34929585
Sleep disorder due to a general medical condition 112.26 12.26 62 26596 5159 34925114
Mite allergy 111.87 12.26 35 26623 667 34929606
Dust allergy 107.03 12.26 36 26622 870 34929403
Antimicrobial susceptibility test resistant 105.33 12.26 29 26629 345 34929928
Orthostatic hypotension 102.20 12.26 112 26546 25807 34904466
Minimum inhibitory concentration 94.69 12.26 23 26635 159 34930114
Therapeutic response delayed 85.98 12.26 28 26630 610 34929663
Urinary retention 80.95 12.26 118 26540 36170 34894103
Breast cancer 79.50 12.26 22 26636 267 34930006
Asthma 78.68 12.26 127 26531 42529 34887744
Wrong patient received product 78.43 12.26 39 26619 2615 34927658
Sopor 74.95 12.26 67 26591 12069 34918204
Gynaecomastia 70.51 12.26 60 26598 10120 34920153
Toxicity to various agents 65.01 12.26 36 26622 200326 34729947
Wheezing 62.78 12.26 113 26545 41289 34888984
Breast tenderness 54.68 12.26 21 26637 750 34929523
Normochromic normocytic anaemia 53.65 12.26 36 26622 4251 34926022
Prostate cancer 49.94 12.26 100 26558 39549 34890724
Product administration error 48.38 12.26 61 26597 16283 34913990
Fall 47.90 12.26 291 26367 202594 34727679
Dysuria 47.55 12.26 79 26579 27073 34903200
Product dispensing error 45.55 12.26 38 26620 6236 34924037
Breast pain 45.23 12.26 22 26636 1406 34928867
Full blood count abnormal 44.98 12.26 63 26595 18605 34911668
Completed suicide 44.81 12.26 10 26648 98158 34832115
Expired product administered 44.09 12.26 29 26629 3312 34926961
Nipple pain 40.80 12.26 18 26640 919 34929354
Wrong product administered 40.17 12.26 33 26625 5301 34924972
Prostatomegaly 40.13 12.26 33 26625 5308 34924965
Product storage error 38.97 12.26 39 26619 8083 34922190
Dyspnoea 38.80 12.26 448 26210 376334 34553939
Erectile dysfunction 37.42 12.26 61 26597 20576 34909697
Foveal degeneration 37.08 12.26 6 26652 0 34930273
Prostatic specific antigen increased 34.56 12.26 49 26609 14631 34915642
Syncope 33.98 12.26 149 26509 91302 34838971
Breast enlargement 33.36 12.26 13 26645 483 34929790
5-alpha-reductase deficiency 32.92 12.26 6 26652 6 34930267
Cardiac failure 32.64 12.26 147 26511 91101 34839172
Asthenia 30.96 12.26 304 26354 244947 34685326
Forced vital capacity decreased 30.89 12.26 14 26644 762 34929511
Tachyarrhythmia 30.74 12.26 24 26634 3584 34926689
Productive cough 30.52 12.26 80 26578 37733 34892540
Vertigo 30.48 12.26 63 26595 25473 34904800
Nodule 29.56 12.26 31 26627 6788 34923485
Subarachnoid haematoma 29.15 12.26 10 26648 257 34930016
Pulmonary function test abnormal 28.15 12.26 20 26638 2590 34927683
Dark circles under eyes 28.03 12.26 7 26651 55 34930218
Drug abuse 26.48 12.26 22 26636 99074 34831199
Drug interaction 26.07 12.26 275 26383 225671 34704602
Ossicle disorder 26.03 12.26 6 26652 32 34930241
Malaise 25.74 12.26 235 26423 185590 34744683
Arteriosclerosis coronary artery 25.53 12.26 39 26619 12446 34917827
Haematuria 25.41 12.26 90 26568 49976 34880297
Obesity 24.62 12.26 39 26619 12839 34917434
Diffuse idiopathic skeletal hyperostosis 24.16 12.26 6 26652 46 34930227
Hyponatraemic syndrome 23.79 12.26 8 26650 193 34930080
Cerebral haematoma 23.70 12.26 23 26635 4592 34925681
Disorganised speech 22.96 12.26 12 26646 893 34929380
Breast induration 22.48 12.26 4 26654 3 34930270
Eye haematoma 22.30 12.26 6 26652 65 34930208
Rectal haemorrhage 21.85 12.26 74 26584 40175 34890098
Multiple organ dysfunction syndrome 21.71 12.26 16 26642 76550 34853723
Gait disturbance 21.22 12.26 124 26534 85016 34845257
Product dose omission issue 20.93 12.26 37 26621 119674 34810599
Breast mass 20.69 12.26 10 26648 630 34929643
Pollakiuria 20.56 12.26 46 26612 19628 34910645
Presyncope 20.41 12.26 45 26613 19014 34911259
Myoclonic epilepsy 20.21 12.26 12 26646 1145 34929128
FEV1/FVC ratio decreased 19.81 12.26 6 26652 102 34930171
Subdural haematoma 19.41 12.26 46 26612 20375 34909898
Semen volume decreased 19.34 12.26 8 26650 348 34929925
Sepsis 19.23 12.26 64 26594 166497 34763776
Invasive ductal breast carcinoma 19.13 12.26 5 26653 48 34930225
Genitalia external ambiguous 18.95 12.26 7 26651 224 34930049
Loss of personal independence in daily activities 18.90 12.26 62 26596 33117 34897156
Intraventricular haemorrhage 18.89 12.26 18 26640 3513 34926760
Drug ineffective 18.77 12.26 241 26417 456510 34473763
Lower urinary tract symptoms 18.66 12.26 7 26651 234 34930039
Obstructive airways disorder 18.22 12.26 38 26620 15456 34914817
Breast cancer male 18.18 12.26 8 26650 406 34929867
Procedural haemorrhage 18.08 12.26 15 26643 2442 34927831
Pemphigoid 17.62 12.26 27 26631 8639 34921634
Autonomic nervous system imbalance 17.59 12.26 15 26643 2536 34927737
Death 17.48 12.26 207 26451 397842 34532431
Occupational exposure to air contaminants 17.35 12.26 6 26652 158 34930115
Urine flow decreased 16.91 12.26 11 26647 1233 34929040
Pain 16.61 12.26 90 26568 204585 34725688
Asthma-chronic obstructive pulmonary disease overlap syndrome 16.57 12.26 11 26647 1276 34928997
Loss of consciousness 16.04 12.26 113 26545 82554 34847719
Nausea 16.00 12.26 174 26484 339734 34590539
Hyperkalaemia 15.97 12.26 99 26559 69290 34860983
Wrong strength 15.57 12.26 5 26653 104 34930169
Tongue oedema 15.51 12.26 15 26643 2982 34927291
Respiratory symptom 15.41 12.26 12 26646 1785 34928488
Foetal exposure during pregnancy 15.27 12.26 5 26653 38096 34892177
Urinary tract infection 15.19 12.26 113 26545 83968 34846305
Hepatocellular injury 14.96 12.26 44 26614 22167 34908106
Haemorrhage 14.92 12.26 78 26580 51292 34878981
Libido decreased 14.65 12.26 18 26640 4678 34925595
Atrial fibrillation 14.56 12.26 150 26508 122243 34808030
Prostatic haemorrhage 14.50 12.26 6 26652 261 34930012
Treatment failure 14.25 12.26 9 26649 46688 34883585
Medical device site haemorrhage 14.24 12.26 5 26653 138 34930135
Febrile neutropenia 14.18 12.26 55 26603 136794 34793479
Off label use 14.18 12.26 230 26428 419294 34510979
Abnormal sleep-related event 13.93 12.26 7 26651 480 34929793
Hypoglycaemia 13.88 12.26 80 26578 54560 34875713
Cardio-respiratory arrest 13.88 12.26 13 26645 55260 34875013
Blood immunoglobulin E increased 13.66 12.26 13 26645 2533 34927740
Arteriosclerosis 13.66 12.26 29 26629 11939 34918334
Product use in unapproved indication 13.65 12.26 45 26613 117454 34812819
Dyspnoea exertional 13.47 12.26 67 26591 43212 34887061
Body mass index increased 13.38 12.26 9 26649 1066 34929207
Cough 13.38 12.26 174 26484 149966 34780307
Vascular dementia 13.36 12.26 7 26651 524 34929749
Blood gases abnormal 13.25 12.26 6 26652 326 34929947
Blood pressure systolic increased 13.17 12.26 43 26615 22909 34907364
Lactic acidosis 13.16 12.26 57 26601 34715 34895558
Benign prostatic hyperplasia 13.08 12.26 32 26626 14463 34915810
Forced expiratory volume decreased 12.89 12.26 14 26644 3189 34927084
Breast disorder male 12.86 12.26 3 26655 17 34930256
Hyperkeratosis 12.73 12.26 15 26643 3734 34926539
Testicular pain 12.55 12.26 13 26645 2805 34927468
Sputum increased 12.53 12.26 12 26646 2358 34927915
Respiratory arrest 12.50 12.26 3 26655 28040 34902233
Lung hyperinflation 12.33 12.26 8 26650 892 34929381

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Conjunctivitis allergic 142.68 13.08 41 21774 1679 79720894
Spirometry abnormal 131.68 13.08 34 21781 925 79721648
Antimicrobial susceptibility test resistant 128.23 13.08 28 21787 360 79722213
Mite allergy 123.29 13.08 34 21781 1196 79721377
Drug dispensed to wrong patient 121.58 13.08 30 21785 676 79721897
Dust allergy 120.23 13.08 35 21780 1501 79721072
Minimum inhibitory concentration 118.43 13.08 23 21792 157 79722416
Mycotic allergy 116.20 13.08 34 21781 1485 79721088
Sleep disorder due to a general medical condition 107.89 13.08 60 21755 14217 79708356
Orthostatic hypotension 102.84 13.08 100 21715 56064 79666509
Therapeutic response delayed 93.73 13.08 27 21788 1115 79721458
Urinary retention 77.01 13.08 86 21729 56544 79666029
Sopor 76.38 13.08 67 21748 32943 79689630
Prostate cancer 75.93 13.08 67 21748 33201 79689372
Wrong patient received product 69.49 13.08 31 21784 4587 79717986
Drug interaction 69.40 13.08 260 21555 414923 79307650
Gynaecomastia 62.78 13.08 34 21781 7647 79714926
Normochromic normocytic anaemia 62.59 13.08 34 21781 7693 79714880
Cardiac failure 56.08 13.08 128 21687 154714 79567859
Wheezing 54.49 13.08 107 21708 116557 79606016
Asthma 53.79 13.08 116 21699 134979 79587594
Syncope 52.87 13.08 137 21678 179312 79543261
Haematuria 51.77 13.08 78 21737 68758 79653815
Expired product administered 51.55 13.08 29 21786 7022 79715551
Erectile dysfunction 49.24 13.08 37 21778 14627 79707946
Pain 48.10 13.08 74 21741 703728 79018845
Product dispensing error 47.98 13.08 35 21780 13228 79709345
Full blood count abnormal 47.52 13.08 57 21758 40417 79682156
Wrong product administered 47.45 13.08 30 21785 8982 79713591
Fall 47.28 13.08 260 21555 487369 79235204
Toxicity to various agents 45.09 13.08 30 21785 421510 79301063
Arteriosclerosis coronary artery 44.94 13.08 38 21777 17778 79704795
Completed suicide 44.48 13.08 7 21808 245760 79476813
Product administration error 42.66 13.08 48 21767 31798 79690775
Nipple pain 42.43 13.08 14 21801 912 79721661
Acute kidney injury 41.98 13.08 264 21551 519140 79203433
Prostatomegaly 41.84 13.08 20 21795 3463 79719110
Hyperkalaemia 40.77 13.08 94 21721 114304 79608269
Dyspnoea 39.94 13.08 383 21432 856642 78865931
Atrial fibrillation 39.04 13.08 131 21684 197755 79524818
Asthenia 38.83 13.08 256 21559 511433 79211140
Tachyarrhythmia 38.73 13.08 24 21791 6938 79715635
Subarachnoid haematoma 38.28 13.08 10 21805 285 79722288
Prostatic specific antigen increased 36.65 13.08 27 21788 10359 79712214
Pulmonary function test abnormal 35.70 13.08 19 21796 4125 79718448
Nausea 34.54 13.08 140 21675 957056 78765517
Productive cough 34.17 13.08 75 21740 88256 79634317
Drug intolerance 33.75 13.08 15 21800 264104 79458469
Cerebral haematoma 33.45 13.08 23 21792 7919 79714654
Subdural haematoma 33.24 13.08 42 21773 31392 79691181
Dysuria 33.11 13.08 54 21761 50897 79671676
Treatment failure 32.86 13.08 4 21811 170482 79552091
Ossicle disorder 32.16 13.08 6 21809 32 79722541
Rectal haemorrhage 32.06 13.08 67 21748 76233 79646340
Alopecia 31.40 13.08 12 21803 231343 79491230
Forced vital capacity decreased 30.45 13.08 13 21802 1730 79720843
Drug ineffective 30.31 13.08 173 21642 1080740 78641833
Breast tenderness 30.25 13.08 14 21801 2254 79720319
Joint swelling 30.23 13.08 21 21794 288625 79433948
Intraventricular haemorrhage 30.14 13.08 18 21797 4869 79717704
Product storage error 29.88 13.08 29 21786 16197 79706376
Diffuse idiopathic skeletal hyperostosis 29.53 13.08 6 21809 53 79722520
Semen volume decreased 28.42 13.08 6 21809 65 79722508
Vertigo 27.11 13.08 59 21756 69023 79653550
Obstructive airways disorder 27.06 13.08 38 21777 31421 79691152
Hypoglycaemia 26.31 13.08 74 21741 101520 79621053
Pemphigoid 25.66 13.08 26 21789 15289 79707284
Contraindicated product administered 25.30 13.08 6 21809 157532 79565041
Lactic acidosis 25.26 13.08 58 21757 70301 79652272
Disorganised speech 24.96 13.08 12 21803 2105 79720468
Therapeutic product effect decreased 24.86 13.08 7 21808 163856 79558717
Arteriosclerosis 23.61 13.08 27 21788 18200 79704373
Occupational exposure to air contaminants 23.42 13.08 6 21809 158 79722415
Eye haematoma 23.28 13.08 6 21809 162 79722411
Infusion related reaction 22.49 13.08 18 21797 230219 79492354
Dyspnoea exertional 22.13 13.08 63 21752 87010 79635563
Presyncope 22.06 13.08 40 21775 41014 79681559
Lower urinary tract symptoms 21.92 13.08 6 21809 205 79722368
Benign prostatic hyperplasia 21.85 13.08 21 21794 11591 79710982
Breast enlargement 21.79 13.08 10 21805 1579 79720994
Gait disturbance 21.63 13.08 113 21702 207393 79515180
Nodule 21.62 13.08 29 21786 22965 79699608
Breast pain 21.61 13.08 18 21797 8247 79714326
Hepatocellular injury 21.41 13.08 43 21772 47550 79675023
FEV1/FVC ratio decreased 21.36 13.08 6 21809 226 79722347
Hyponatraemic syndrome 21.21 13.08 8 21807 772 79721801
Obesity 21.18 13.08 36 21779 35089 79687484
Chronic obstructive pulmonary disease 20.93 13.08 61 21754 85358 79637215
Dark circles under eyes 20.87 13.08 7 21808 480 79722093
Procedural haemorrhage 20.70 13.08 14 21801 4692 79717881
Haemorrhage 20.37 13.08 63 21752 91055 79631518
Pulmonary embolism 19.66 13.08 96 21719 171558 79551015
Loss of consciousness 19.29 13.08 94 21721 167849 79554724
Hand deformity 18.70 13.08 3 21812 103916 79618657
Arthralgia 18.50 13.08 87 21728 571716 79150857
Pollakiuria 18.35 13.08 35 21780 37282 79685291
Rheumatoid arthritis 18.31 13.08 18 21797 208452 79514121
Headache 18.05 13.08 105 21710 653667 79068906
Medical device site haemorrhage 17.96 13.08 5 21810 182 79722391
Wrong strength 17.91 13.08 5 21810 184 79722389
Asthma-chronic obstructive pulmonary disease overlap syndrome 17.65 13.08 11 21804 3210 79719363
Penile abscess 17.46 13.08 3 21812 9 79722564
Breast disorder male 17.22 13.08 3 21812 10 79722563
Testicular swelling 17.21 13.08 8 21807 1302 79721271
Epididymitis 17.05 13.08 9 21806 1921 79720652
Body mass index increased 17.04 13.08 9 21806 1924 79720649
Inferior vena cava dilatation 16.90 13.08 7 21808 864 79721709
Thrombosis 16.85 13.08 56 21759 84044 79638529
Vascular dementia 16.84 13.08 7 21808 872 79721701
Abnormal sleep-related event 16.76 13.08 7 21808 882 79721691
Pulmonary interstitial emphysema syndrome 16.56 13.08 6 21809 517 79722056
Hypoaesthesia 16.31 13.08 15 21800 179337 79543236
Left ventricular dysfunction 16.08 13.08 23 21792 19338 79703235
Renal failure 16.07 13.08 102 21713 200866 79521707
Respiratory symptom 15.89 13.08 12 21803 4779 79717794
Blood immunoglobulin E increased 15.77 13.08 13 21802 5869 79716704
Bronchial hyperreactivity 15.70 13.08 10 21805 3030 79719543
Blood testosterone increased 15.63 13.08 7 21808 1045 79721528
Facial bones fracture 15.26 13.08 12 21803 5070 79717503
Urine flow decreased 15.20 13.08 7 21808 1114 79721459
Cerebral haemorrhage 14.92 13.08 42 21773 57631 79664942
Brain stem haematoma 14.90 13.08 4 21811 127 79722446
Clostridium test positive 14.72 13.08 13 21802 6441 79716132
Violence-related symptom 14.61 13.08 6 21809 725 79721848
Malaise 14.60 13.08 201 21614 489668 79232905
Hyperkeratosis 14.49 13.08 14 21801 7776 79714797
Hypoxia 14.24 13.08 61 21754 103182 79619391
Product dose omission issue 14.16 13.08 29 21786 247508 79475065
Sputum increased 14.08 13.08 11 21804 4602 79717971
Arthropathy 13.67 13.08 17 21798 177094 79545479
Toxic skin eruption 13.64 13.08 23 21792 22270 79700303
Tongue oedema 13.63 13.08 13 21802 7104 79715469
Depression 13.62 13.08 24 21791 216766 79505807
Bronchiectasis 13.57 13.08 23 21792 22363 79700210
Vomiting 13.46 13.08 117 21698 665711 79056862
Peripheral sensorimotor neuropathy 13.35 13.08 9 21806 3001 79719572
Breast induration 13.31 13.08 3 21812 45 79722528

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC G04CA52 GENITO URINARY SYSTEM AND SEX HORMONES
UROLOGICALS
DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY
Alpha-adrenoreceptor antagonists
ATC G04CB02 GENITO URINARY SYSTEM AND SEX HORMONES
UROLOGICALS
DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY
Testosterone-5-alpha reductase inhibitors
FDA MoA N0000000126 5-alpha Reductase Inhibitors
MeSH PA D058891 5-alpha Reductase Inhibitors
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D006727 Hormone Antagonists
MeSH PA D065088 Steroid Synthesis Inhibitors
FDA EPC N0000175836 5-alpha Reductase Inhibitor

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Benign prostatic hyperplasia indication 266569009
Priapism contraindication 6273006 DOID:9286
Orthostatic hypotension contraindication 28651003
Oligozoospermia contraindication 88311004
Cataract surgery contraindication 110473004
Disease of liver contraindication 235856003 DOID:409
Syncope contraindication 271594007
Pregnancy, function contraindication 289908002
Dizziness contraindication 404640003
Breastfeeding (mother) contraindication 413712001
Intraoperative floppy iris syndrome contraindication 418801006
High-Grade Prostate Cancer contraindication




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 12.41 acidic
pKa2 13.26 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
3-oxo-5-alpha-steroid 4-dehydrogenase 2 Enzyme INHIBITOR IC50 9.20 WOMBAT-PK CHEMBL
3-oxo-5-alpha-steroid 4-dehydrogenase 1 Enzyme INHIBITOR IC50 8.49 WOMBAT-PK CHEMBL
Glycine receptor subunit alpha-1 Ion channel EC50 6.48 CHEMBL

External reference:

IDSource
4021371 VUID
N0000148790 NUI
D03820 KEGG_DRUG
4021371 VANDF
C0754659 UMLSCUI
CHEMBL1200969 ChEMBL_ID
D000068538 MESH_DESCRIPTOR_UI
DB01126 DRUGBANK_ID
7457 IUPHAR_LIGAND_ID
7586 INN_ID
O0J6XJN02I UNII
6918296 PUBCHEM_CID
228790 RXNORM
16302 MMSL
228246 MMSL
42738 MMSL
d04788 MMSL
009824 NDDF
385570006 SNOMEDCT_US
385572003 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Dutasteride HUMAN PRESCRIPTION DRUG LABEL 1 0115-1438 CAPSULE, LIQUID FILLED 0.50 mg ORAL ANDA 28 sections
AVODART HUMAN PRESCRIPTION DRUG LABEL 1 0173-0712 CAPSULE, LIQUID FILLED 0.50 mg ORAL NDA 27 sections
JALYN HUMAN PRESCRIPTION DRUG LABEL 2 0173-0809 CAPSULE 0.50 mg ORAL NDA 29 sections
JALYN HUMAN PRESCRIPTION DRUG LABEL 2 0173-0809 CAPSULE 0.50 mg ORAL NDA 29 sections
Dutasteride HUMAN PRESCRIPTION DRUG LABEL 1 0173-7077 CAPSULE, LIQUID FILLED 0.50 mg ORAL Export only 2 sections
Dutasteride and Tamsulosin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 2 10370-280 CAPSULE 0.50 mg ORAL ANDA 28 sections
Dutasteride and Tamsulosin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 2 10370-280 CAPSULE 0.50 mg ORAL ANDA 28 sections
Dutasteride Human Prescription Drug Label 1 25000-011 CAPSULE, LIQUID FILLED 0.50 mg ORAL ANDA 29 sections
Dutasteride HUMAN PRESCRIPTION DRUG LABEL 1 31722-131 CAPSULE, LIQUID FILLED 0.50 mg ORAL ANDA 18 sections
Dutasteride HUMAN PRESCRIPTION DRUG LABEL 1 42806-549 CAPSULE, LIQUID FILLED 0.50 mg ORAL ANDA 28 sections
Dutasteride HUMAN PRESCRIPTION DRUG LABEL 1 50090-4010 CAPSULE, LIQUID FILLED 0.50 mg ORAL ANDA 18 sections
Dutasteride HUMAN PRESCRIPTION DRUG LABEL 1 51013-190 CAPSULE, LIQUID FILLED 0.50 mg ORAL ANDA 28 sections
Dutasteride HUMAN PRESCRIPTION DRUG LABEL 1 51407-157 CAPSULE, LIQUID FILLED 0.50 mg ORAL ANDA 18 sections
Dutasteride HUMAN PRESCRIPTION DRUG LABEL 1 51407-157 CAPSULE, LIQUID FILLED 0.50 mg ORAL ANDA 18 sections
Dutasteride HUMAN PRESCRIPTION DRUG LABEL 1 53345-037 CAPSULE, LIQUID FILLED 0.50 mg ORAL ANDA 28 sections
Avodart HUMAN PRESCRIPTION DRUG LABEL 1 54868-5114 CAPSULE, LIQUID FILLED 0.50 mg ORAL NDA 27 sections
JALYN HUMAN PRESCRIPTION DRUG LABEL 2 54868-6328 CAPSULE 0.50 mg ORAL NDA 28 sections
Dutasteride Human Prescription Drug Label 1 59651-021 CAPSULE, LIQUID FILLED 0.50 mg ORAL ANDA 28 sections
Dutasteride HUMAN PRESCRIPTION DRUG LABEL 1 62112-8068 CAPSULE, LIQUID FILLED 0.50 mg ORAL ANDA 27 sections
Dutasteride HUMAN PRESCRIPTION DRUG LABEL 1 63629-1222 CAPSULE, LIQUID FILLED 0.50 mg ORAL ANDA 18 sections
Dutasteride HUMAN PRESCRIPTION DRUG LABEL 1 63629-1222 CAPSULE, LIQUID FILLED 0.50 mg ORAL ANDA 18 sections
Dutasteride HUMAN PRESCRIPTION DRUG LABEL 1 63629-1222 CAPSULE, LIQUID FILLED 0.50 mg ORAL ANDA 18 sections
Dutasteride HUMAN PRESCRIPTION DRUG LABEL 1 63629-1223 CAPSULE, LIQUID FILLED 0.50 mg ORAL ANDA 18 sections
Dutasteride HUMAN PRESCRIPTION DRUG LABEL 1 63629-1223 CAPSULE, LIQUID FILLED 0.50 mg ORAL ANDA 18 sections
Dutasteride HUMAN PRESCRIPTION DRUG LABEL 1 63629-1223 CAPSULE, LIQUID FILLED 0.50 mg ORAL ANDA 18 sections
Dutasteride HUMAN PRESCRIPTION DRUG LABEL 1 63629-8207 CAPSULE, LIQUID FILLED 0.50 mg ORAL ANDA 18 sections
Dutasteride HUMAN PRESCRIPTION DRUG LABEL 1 63629-8207 CAPSULE, LIQUID FILLED 0.50 mg ORAL ANDA 18 sections
Dutasteride HUMAN PRESCRIPTION DRUG LABEL 1 64380-763 CAPSULE, LIQUID FILLED 0.50 mg ORAL ANDA 25 sections
DUTASTERIDE HUMAN PRESCRIPTION DRUG LABEL 1 64980-224 CAPSULE, LIQUID FILLED 0.50 mg ORAL ANDA 26 sections
Dutasteride HUMAN PRESCRIPTION DRUG LABEL 1 65162-750 CAPSULE 0.50 mg ORAL ANDA 18 sections